NCT05701709View on ClinicalTrials.gov

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-A2102

SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY